These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 38211602)

  • 21. Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron.
    Amano M; Otsu S; Uemura Y; Ichikawa Y; Matsumoto S; Higashi-Kuwata N; Matsushita S; Shimada S; Mitsuya H
    Sci Rep; 2023 Oct; 13(1):17404. PubMed ID: 37833390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Humoral Response and SARS-CoV-2 Infection Risk following the Third and Fourth Doses of the BNT162b2 Vaccine in Dialysis Patients.
    Einbinder Y; Perl J; Nacasch N; Bnaya A; Shavit L; Erez D; Shashar M; Halperin T; Grupper A; Benchetrit S; Wand O; Cohen-Hagai K
    Am J Nephrol; 2022; 53(7):586-590. PubMed ID: 35850101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis.
    Sibbel S; McKeon K; Luo J; Wendt K; Walker AG; Kelley T; Lazar R; Zywno ML; Connaire JJ; Tentori F; Young A; Brunelli SM
    J Am Soc Nephrol; 2022 Jan; 33(1):49-57. PubMed ID: 34789546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients.
    Davidovic T; Schimpf J; Abbassi-Nik A; Stockinger R; Sprenger-Mähr H; Lhotta K; Zitt E
    Front Immunol; 2022; 13():907615. PubMed ID: 35812459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.
    Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM
    Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children.
    Bellusci L; Grubbs G; Sait S; Yonker LM; Randolph AG; Novak T; Kobayashi T; ; Khurana S
    Nat Commun; 2023 Dec; 14(1):7952. PubMed ID: 38040697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccination against SARS-CoV-2 in Haemodialysis Patients: Spike's Ab Response and the Influence of BMI and Age.
    Ponce P; Peralta R; Felix C; Pinto C; Pinto B; Matos JF
    Int J Environ Res Public Health; 2022 Aug; 19(16):. PubMed ID: 36011725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Superior cellular and humoral immunity toward SARS-CoV-2 reference and alpha and beta VOC strains in COVID-19 convalescent as compared to the prime boost BNT162b2-vaccinated dialysis patients.
    Blazquez-Navarro A; Safi L; Meister TL; Thieme CJ; Kaliszczyk S; Paniskaki K; Stockhausen M; Hörstrup J; Cinkilic O; Flitsch-Kiefner L; Marheinecke C; Steinmann E; Seibert FS; Stervbo U; Westhoff TH; Pfaender S; Roch T; Babel N
    Kidney Int; 2021 Sep; 100(3):698-700. PubMed ID: 34273381
    [No Abstract]   [Full Text] [Related]  

  • 29. Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer.
    Debie Y; Van Audenaerde JRM; Vandamme T; Croes L; Teuwen LA; Verbruggen L; Vanhoutte G; Marcq E; Verheggen L; Le Blon D; Peeters B; Goossens ME; Pannus P; Ariën KK; Anguille S; Janssens A; Prenen H; Smits ELJ; Vulsteke C; Lion E; Peeters M; van Dam PA
    Clin Cancer Res; 2023 Feb; 29(3):635-646. PubMed ID: 36341493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of humoral and cellular immune responses to SARS CoV-2 vaccination (BNT162b2) in immunocompromised renal allograft recipients.
    Zhang R; Shin BH; Gadsden TM; Petrosyan A; Vo A; Ammerman N; Sethi S; Huang E; Peng A; Najjar R; Atienza J; Kim I; Jordan SC
    Transpl Infect Dis; 2022 Apr; 24(2):e13813. PubMed ID: 35202497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial.
    Blixt L; Wullimann D; Aleman S; Lundin J; Chen P; Gao Y; Cuapio A; Akber M; Lange J; Rivera-Ballesteros O; Buggert M; Ljunggren HG; Hansson L; Österborg A
    Haematologica; 2022 Apr; 107(4):1000-1003. PubMed ID: 35045694
    [No Abstract]   [Full Text] [Related]  

  • 32. A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen.
    Baek YJ; Kim WJ; Ko JH; Lee YJ; Ahn JY; Kim JH; Jang HC; Jeong HW; Kim YC; Park YS; Kim SH; Peck KR; Shin EC; Choi JY
    Vaccine; 2023 Mar; 41(10):1694-1702. PubMed ID: 36754764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The DiaCoVAb Study in South Italy: Immune Response to SARS-CoV-2 Vaccination in Dialysis Patients.
    Fucci A; Giacobbe S; Guerriero I; Suzumoto Y; D'Andrea EL; Scrima M; Nolli ML; Iervolino A; Chiuchiolo LA; Salvatore E; Renzulli R; La Peccerella L; Marra G; Liuzzi M; Santoro D; Zulli E; Gentile R; Clemente G; Capasso G
    Kidney Blood Press Res; 2022; 47(7):467-474. PubMed ID: 35318291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination.
    Gonzalez-Perez M; Montes-Casado M; Conde P; Cervera I; Baranda J; Berges-Buxeda MJ; Perez-Olmeda M; Sanchez-Tarjuelo R; Utrero-Rico A; Lozano-Ojalvo D; Torre D; Schwarz M; Guccione E; Camara C; Llópez-Carratalá MR; Gonzalez-Parra E; Portoles P; Ortiz A; Portoles J; Ochando J
    Front Immunol; 2022; 13():845882. PubMed ID: 35401504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impaired Immune Response to SARS-CoV-2 Vaccination in Dialysis Patients and in Kidney Transplant Recipients.
    Kolb T; Fischer S; Müller L; Lübke N; Hillebrandt J; Andrée M; Schmitz M; Schmidt C; Küçükköylü S; Koster L; Kittel M; Weiland L; Dreyling KW; Hetzel G; Adams O; Schaal H; Ivens K; Rump LC; Timm J; Stegbauer J
    Kidney360; 2021 Sep; 2(9):1491-1498. PubMed ID: 35373105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2 mRNA vaccination is not associated with the induction of anti-HLA or non-HLA antibodies.
    Wijtvliet VPWM; Verheyden S; Depreter B; Heylen C; Coeman E; Abrams S; De Winter BY; Massart A; Hellemans R; Pipeleers L; Claas FHJ; Ariën KK; Wissing KM; Abramowicz D; Ledeganck KJ
    Transpl Immunol; 2022 Oct; 74():101670. PubMed ID: 35835296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rheumatoid arthritis patients treated with Janus kinase inhibitors show reduced humoral immune responses following BNT162b2 vaccination.
    Iancovici L; Khateeb D; Harel O; Peri R; Slobodin G; Hazan Y; Melamed D; Kessel A; Bar-On Y
    Rheumatology (Oxford); 2022 Aug; 61(8):3439-3447. PubMed ID: 34849628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy.
    Jedicke N; Stankov MV; Cossmann A; Dopfer-Jablonka A; Knuth C; Ahrenstorf G; Ramos GM; Behrens GMN
    HIV Med; 2022 May; 23(5):558-563. PubMed ID: 34725907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. B and T cell responses to the 3rd and 4th dose of the BNT162b2 vaccine in dialysis patients.
    Bathish Y; Tuvia N; Eshel E; Tal Lange T; Sigrid Eberhardt C; Edelstein M; Abu-Jabal K
    Hum Vaccin Immunother; 2024 Dec; 20(1):2292376. PubMed ID: 38191151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of humoral and cellular immunity after bivalent BNT162b2 vaccination and potential association with reactogenicity.
    Salvagno GL; Pighi L; Henry BM; Valentini M; Tonin B; Bragantini D; Gianfilippi G; De Nitto S; Plebani M; Lippi G
    Clin Chem Lab Med; 2023 Jun; 61(7):1343-1348. PubMed ID: 36722026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.